Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14292730 | 0.87 | TEK (0.45) | TEKHDAC3HDAC6BRAFTRPV1 | |
| SCHEMBL5483879 | 0.86 | TEK (0.46) | TEKHDAC3HDAC6BRAFTRPV1 | |
| SCHEMBL4725070 | 0.81 | TEK (0.46) | TEKBRAFTRPV1 | |
| SCHEMBL4414872 | 0.79 | BRAF (0.49) | TEKBRAFNR1I2NR1H4 | |
| SCHEMBL4726247 | 0.79 | RAF1 (0.43) | TEKBRAF | |
| SCHEMBL4725698 | 0.78 | RAF1 (0.48) | TEKBRAFNR1H4 | |
| SCHEMBL4727623 | 0.78 | NR1I2 (0.48) | TEKBRAFNR1I2EGLN2 | |
| SCHEMBL4727508 | 0.77 | RAF1 (0.47) | TEKBRAF | |
| SCHEMBL4410252 | 0.77 | BRAF (0.46) | TEKBRAF | |
| SCHEMBL4726798 | 0.77 | RAF1 (0.42) | TEKHDAC3HDAC6BRAFTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |